Deltec Asset Management’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Deltec Asset Management’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-15,000	Closed	-$346K	–	347
2020 Q4	$346K	Buy	+15,000	New	+$190K	0.05%	185

Deltec Asset Management's PRVL Position: Q1 2021 in Review

Deltec Asset Management sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 15,000 shares — an estimated $346K sold.

Deltec Asset Management first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $346K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Deltec Asset Management reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Deltec Asset Management sold 15,000 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $346K.
Deltec Asset Management first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Deltec Asset Management's Prevail Therapeutics Inc. Common Stock position peaked at $346K in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Deltec Asset Management's 13F filing for Q1 2021, filed 21 Apr 2021.